Pneumovax 23

Pneumococcal Vaccine Polyvalent


Merck Sharp & Dohme Llc
Vaccine
NDC 0006-4943
Pneumovax 23 also known as Pneumococcal Vaccine Polyvalent is a vaccine labeled by 'Merck Sharp & Dohme Llc'. National Drug Code (NDC) number for Pneumovax 23 is 0006-4943. This drug is available in dosage form of Injection, Solution. The names of the active, medicinal ingredients in Pneumovax 23 drug includes Streptococcus Pneumoniae Type 1 Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 10a Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 11a Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 12f Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 14 Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 15b Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 17f Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 18c Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 19a Capsular Polysaccharide Antigen - 25 ug/.5mL Streptococcus Pneumoniae Type 19f Capsular Polysaccharide Antigen - 25 ug/.5mL and more. The currest status of Pneumovax 23 drug is Active.

Drug Information:

Drug NDC: 0006-4943
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Pneumovax 23
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Vaccine
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Pneumococcal Vaccine Polyvalent
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Merck Sharp & Dohme Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection, Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:STREPTOCOCCUS PNEUMONIAE TYPE 1 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 10A CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 11A CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 12F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 14 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 15B CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 17F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 18C CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 19A CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 19F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 2 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 20 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 22F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 23F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 3 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 33F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 4 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 5 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 6B CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 7F CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 8 CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 9N CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
STREPTOCOCCUS PNEUMONIAE TYPE 9V CAPSULAR POLYSACCHARIDE ANTIGEN - 25 ug/.5mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAMUSCULAR
SUBCUTANEOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: BLA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 07 Jul, 1983
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 27 Dec, 2024
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: BLA101094
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
UNII:
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Actively Acquired Immunity [PE]
Inactivated Pneumococcal Vaccine [EPC]
Pneumococcal Vaccines [CS]
Vaccines
Inactivated [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0006-4943-0010 VIAL, SINGLE-DOSE in 1 CARTON (0006-4943-00) / .5 mL in 1 VIAL, SINGLE-DOSE (0006-4943-01)07 Jul, 1983N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.